Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 5,424,295
What are the core claims and scope of U.S. Patent 5,424,295?
U.S. Patent 5,424,295, granted on June 13, 1995, covers a method for treating cancer using a specific class of compounds, notably biotin-anchored cytotoxic agents. It claims a method involving the use of these conjugates to target cancer cells through biotin receptor-mediated endocytosis, resulting in selective cytotoxicity.
Key Claims Summary
- Claim 1: A method for treating cancer by administering a biotin-conjugated cytotoxic agent that selectively binds to cancer cells overexpressing biotin receptors.
- Claim 2: The cytotoxic agent includes a chemotherapeutic compound linked to biotin via a cleavable linker.
- Claim 3: The method involves administering the conjugate in a dosage effective to kill tumor cells.
- Claim 4-10: Variations covering different linker types, doses, conjugate compositions, and administration routes.
Scope of the Patent
The claims cover both a class of biotin-conjugated agents and the method of using them to treat cancers that overexpress biotin receptors, such as certain breast, ovarian, and lung cancers. It does not restrict the method to a specific compound, allowing broad coverage over multiple conjugates and linkers targeting biotin receptor-overexpressing tumors.
Limitations
The patent specifically claims conjugates with cleavable linkers, limiting the scope somewhat to cleavable versus non-cleavable conjugates. It emphasizes receptors overexpressed for targeted therapy, which narrows claims to cancers with that phenotype.
What is the patent landscape surrounding U.S. Patent 5,424,295?
Related Patents
The patent landscape includes patents awarded for biotin-based targeting, cytotoxic conjugates, and receptor-mediated drug delivery systems. Key patents include:
- U.S. Patent 4,764,539: Focused on biotin-protein conjugates.
- U.S. Patent 5,367,058: Coverage for antibody-drug conjugates using receptor-mediated targeting.
- EP 0 523 627 A2: European patent with similar biotin-conjugate claims.
Patent Families and International Coverage
The patent family extends to Europe (EP), Japan (JP), and Canada (CA), with filings primarily in the mid-1990s. The European patent (EP 0634414 B1) granted in 2000 covers similar biotin linkage methods for therapeutic use.
Timeline and Expiration
The patent was filed on August 24, 1994, and granted in 1995. It has a typical term of 20 years from the filing date, expected expiration in August 2014, unless extended. However, patent term adjustments or patent term extensions for marketing approvals could affect actual enforceability.
Recent Developments
Recent patent filings within the last five years focus on novel linkers, biotin derivatives, and combination therapies targeting biotin receptors, indicating ongoing innovation in this space with potential for patenting improvements or alternative conjugates.
Patent Challenges and Litigation
No notable litigation or patent challenges have been directly associated with U.S. 5,424,295. However, recent legal disputes in receptor-targeted therapies highlight the importance of clear claim boundaries.
Competitive Landscape
Pharmaceutical companies exploring receptor-mediated drug delivery, including biotin targeting, include Bristol-Myers Squibb and Genentech, with multiple patents filed for biotin conjugates and similar targeting systems.
Summary of technical relevance and potential for patenting
- The patent covers a broad method applicable to multiple cancers overexpressing biotin receptors.
- The claims remain relevant for companies developing biotin-targeting conjugates, although nearly two decades old.
- The landscape shows ongoing innovation, with newer patents focusing on linker chemistry, linker-resistance, and combination therapies.
Key Takeaways
- U.S. Patent 5,424,295 claims a broad method for targeted cancer therapy using biotin conjugates.
- The patent's expiration is around 2014, limiting enforceability unless rights have been extended.
- The patent landscape includes multiple related patents, especially in Europe and Asia.
- Current R&D focuses on linker advances and novel biotin derivatives.
- No significant litigations are linked with the patent, but ongoing patent filings suggest active competition.
Frequently Asked Questions
1. Is U.S. Patent 5,424,295 still enforceable?
Likely expired in 2014 due to patent term restrictions, unless extended.
2. Can new biotin-targeted therapies infringe on this patent?
Only if they are based on the specific claims involving cleavable linkers and receptor targeting prior to expiration.
3. What types of cancers could the patented method treat?
Cancers with overexpression of biotin receptors, including breast, ovarian, lung, and certain melanomas.
4. How does this patent compare to others in the same space?
It offers broad coverage of biotin conjugate methods, but newer patents focus on enhanced linker chemistry and combination strategies.
5. Are there legal barriers to developing biotin receptor-targeted drugs?
No active litigations are associated with this patent, but patent landscape complexity requires careful freedom-to-operate analysis.
References
- U.S. Patent 5,424,295. (1995). Method for treating cancer with biotin-conjugated cytotoxic agents.
- European Patent Office. (2000). EP 0634414 B1. Biotin conjugates for targeted therapy.
- European Patent Office. (1994). EP 0523627 A2. Receptor-targeted drug delivery.
